NOW APPROVED
for adults withBIPOLAR DEPRESSION: 
BIPOLAR I OR II

See the data

Safety & Tolerability

CAPLYTA demonstrated an EPS profile similar to placebo1,3

Incidence of extrapyramidal symptoms (EPS)* and akathisia in acute trials (4- to 6-week)1,3

EPS includes akathisia, extrapyramidal disorder, muscle spasms, restlessness, musculoskeletal stiffness, dyskinesia, dystonia, muscle twitching, tardive dyskinesia, tremor, drooling, and involuntary muscle contractions.1